Angiogenesis in multiple myeloma

Jakob, Christian; Sterz, Jan; Zavrski, Ivana; Heider, Ulrike; Kleeberg, Lorenz; Fleissner, Claudia; Kaiser, Martin; Sezer, Orhan

doi:10.1016/j.ejca.2006.02.017

Cited by 147 publications

(129 citation statements)

References 95 publications

Supporting

Mentioning

115

Contrasting

Unclassified

Order By: Relevance

“…1 This heterogeneity is due to factors intrinsic to the malignant plasma cell as well as due to host factors, which are biological determinants of outcome. In addition to the parameters included in the Durie and Salmon 2 staging system, several clinical and laboratory markers, such as b2-microglobulin (b2M), C-reactive protein, 3 plasma cell proliferative activity (plasma cell labeling index, cell cycle analysis by flow cytometry), 4,5 cytogenetics, 6,7 bone marrow angiogenesis 8,9 or circulating proteasomes 10 were adopted to define risk groups in MM. Although flow cytometry and cytogenetics provide prognostically important information, the broad application of these techniques may have limitations due to costs, standardization and availability.…”

Section: Introductionmentioning

confidence: 99%

Incorporation of the bone marker carboxy-terminal telopeptide of type-1 collagen improves prognostic information of the International Staging System in newly diagnosed symptomatic multiple myeloma

et al. 2008

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Incorporation of the bone marker carboxy-terminal telopeptide of type-1 collagen improves prognostic information of the International Staging System in newly diagnosed symptomatic multiple myeloma

et al. 2008

View full text Add to dashboard Cite

“…Pro-angiogenic factors include vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF). Hematological malignancies are associated with high levels of VEGF and FGF which correlates with advancement of disease stage [66,67]. B-CLL patients were found to have high levels of serum VEGF, which correlated with decreased survival [68].…”

Section: Cox-2/pge 2 Promotes Angiogenesis and Metastasismentioning

confidence: 99%

Targeting Cyclooxygenase-2 in Hematological Malignancies: Rationale and Promise

Bernard¹,

Bancos²,

Sime³

et al. 2008

CPD

View full text Add to dashboard Cite

There is much interest in the potential use of Cox-2 selective inhibitors in combination with other cancer therapeutics. Malignancies of hematopoietic and non-hematopoietic origin often have increased expression of cyclooxygenase-2 (Cox-2), a key modulator of inflammation. For example, hematological malignancies such as chronic lymphocytic leukemia, chronic myeloid leukemia, Hodgkin's lymphoma, non-Hodgkin's lymphoma and multiple myeloma often highly express Cox-2, which correlates with poor patient prognosis. Expression of Cox-2 enhances survival and proliferation of malignant cells, while negatively influencing anti-tumor immunity. Hematological malignancies expressing elevated levels of Cox-2 potentially avoid immune responses by producing factors that enhance angiogenesis and metastases. Cellular immune responses regulated by natural killer cells, cytotoxic T lymphocytes, and T regulatory cells are also influenced by Cox-2 expression. Therefore, Cox-2 selective inhibitors have promising therapeutic potential in patients suffering from certain hematological malignancies.

show abstract

“…This is of potential great clinical relevance since adhesion of aberrant PC to extracellular matrix proteins confers cell adhesion-mediated drug resistance, and triggers BM accessory cells to secrete cytokines (e.g. IL-6, IGF-1, VEGF, BAFF, SDF-1a, and TNFa) which on one side promote PC growth, survival, and migration, at the same time they also confer resistance to conventional chemotherapy (86,87), osteoclastogenesis and angiogenesis (88,89). Because of this, the potential significance of the expression of several markers involved in the interaction between clonal PC and BM stromal cells is currently under investigation; of note, interesting results have already emerged from those studies as regards VLA-4 (90,91), ICAM-1 (CD54) (92), and CD44 (93,94) staining on aberrant PC and their association with the BM PC niches.…”

Section: Utility Of Mfc In MM and Other Plasma Cell Dyscrasiasmentioning

confidence: 99%